RETRACTION

Open Access Full Text Article

Knockdown of Long Noncoding RNA 00152 (LINC00152) Inhibits Human Retinoblastoma Progression [Retraction]

Li S, Wen D, Che S, et al. Onco Targets Ther. 2018;11:3215-3223.

The Editor and Publisher of *OncoTargets and Therapy* wish to retract the published paper. Concerns were raised regarding the alleged manipulation and duplication of tumor images shown in Figure 6B. Specifically:

- Figure 6B, top row images for sh-NC, appear to be duplicated with images of the same tumors in Figure 2D from Liu et al, 2019 (<u>https://doi.org/10.1016/j.biopha.2019.108862</u>) and Figure 6B from Li et al, 2018 (<u>https://doi.org/10.1016/j.biopha.2019.108862</u>).
- Similarly, Figure 6B, bottom row images for sh-LINC00152, also appear to be duplicated with images of the same tumors in Figure 2D from Liu et al, 2019 (<u>https://doi.org/10.1016/j.biopha.2019.108862</u>) and Figure 6B from Li et al, 2018 (<u>https://doi.org/10.1016/j.biopha.2018.03.122</u>).

The authors responded to our queries but could not provide a satisfactory explanation for the alleged duplication or provide adequate raw data for their study. The findings of the study were deemed invalid and the Editor requested for the article to be retracted.

Our decision-making was informed by our policy on publishing ethics and integrity and the COPE guidelines on retraction.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as "Retracted".

OncoTargets and Therapy

Dovepress

119

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/oncotargets-and-therapy-journal

https://doi.org/10.2147/OTT.S358900

Received: 18 January 2022 Accepted: 18 January 2022 Published: 26 January 2022

OncoTargets and Therapy 2022:15 119

© 2022 Dove Medical Press. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/ the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).